In January 2025, BioWorld tracked 171 phase I-III clinical trial updates, down from 212 in December. The month delivered 12 successful phase III outcomes, six of those in cancer, while two trials ...

Datroway shows promising antitumor activity in advanced NSCLC with EGFR mutations and ALK rearrangements, achieving a 35.8% overall response rate. The treatment maintains a manageable safety profile, ...

CHICAGO, February 26, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy, to ...

LIBTAYO (cemiplimab-rwlc) is a prescription medicine used to treat adults with NSCLC. LIBTAYO may be used alone as a first treatment option when your lung cancer has not spread outside your chest ...

Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than Keytruda plus chemotherapy as first-line treatment for patients with ...

fianlimab, which has shown enough promise for the company to launch four phase 3 programs, combining it with its PD-1 inhibitor Libtayo.

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal antibody, chronic graft-versus-host disease and posttransplant ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service. This approval is for second-line monotherapy ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...